Dizal (jiangsu) Pharmaceutical Co. Ltd. Class ASSE: 688192

Voluntary Disclosure Announcement on the Release of the Latest Research Results of DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Conference

· Issued by Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Voluntary Disclosure Announcement on the Release of the Latest Research Results of DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Conference

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis